Intensive Care Management of Sickle Cell Disease

References

[1] WHO/TIF Meeting on the Management of Haemoglobin Disorders (2007: Nicosia C, World Health Organization, Thalassaemia International Federation. Management of haemoglobin disorders: report of a joint WHO-TIF meeting, Nicosia, Cyprus, 16-18 November 2007. 2008; 84.

[2] Serjeant GR. Sickle-cell disease. Lancet Lond Engl 1997; 350: 725–730.

[3] Buchanan GR, DeBaun MR, Quinn CT, et al. Sickle cell disease. Hematol Am Soc Hematol Educ Program 2004; 35–47.

[4] Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. The Lancet 2010; 376: 2018–2031.

[5] Reparaz P, Serrano I, Adan-Pedroso R, et al. Clinical management of the acute complications of sickle cell anemia: 11 years of experience in a tertiary hospital. An Pediatría Engl Ed 2022; 97: 4–11.

[6] Modell B, Darlison M, Birgens H, et al. Epidemiology of haemoglobin disorders in Europe: an overview. Scand J Clin Lab Invest 2007; 67: 39–69.

[7] Fleming AF, Storey J, Molineaux L, et al. Abnormal haemoglobins in the Sudan savanna of Nigeria. I. Prevalence of haemoglobins and relationships between sickle cell trait, malaria and survival. Ann Trop Med Parasitol 1979; 73: 161–172.

[8] Ware RE, de Montalembert M, Tshilolo L, et al. Sickle cell disease. Lancet Lond Engl 2017; 390: 311–323.

[9] Perronne V, Roberts-Harewood M, Bachir D, et al. Patterns of mortality in sickle cell disease in adults in France and England. Hematol J Off J Eur Haematol Assoc 2002; 3: 56–60.

[10] Manci EA, Culberson DE, Yang Y-M, et al. Causes of death in sickle cell disease: an autopsy study. Br J Haematol 2003; 123: 359–365.

[11] Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994; 330: 1639–1644.

[12] Agbakou M, Mekontso-Dessap A, Pere M, et al. Nationwide retrospective study of critically ill adults with sickle cell disease in France. Sci Rep 2021; 11: 23132.

[13] Gardner K, Douiri A, Drasar E, et al. Survival in adults with sickle cell disease in a high-income setting. Blood 2016; 128: 1436–1438.

[14] Cecchini J, Fartoukh M. Sickle cell disease in the ICU. Curr Opin Crit Care 2015; 21: 569–575.

[15] Tawfic Q, Kausalya R, Burad J, et al. Adult Sickle Cell Disease: A Five-Year Experience of Intensive Care Management in a University Hospital in Oman. Sultan Qaboos Univ Med J 2012; 12: 177–83.

[16] Abd Rahman R, DeKoninck P, Murthi P, et al. Treatment of preeclampsia with hydroxychloroquine: a review. J Matern-Fetal Neonatal Med Off J Eur Assoc Perinat Med Fed Asia Ocean Perinat Soc Int Soc Perinat Obstet 2018; 31: 525–529.

[17] Simpson JL. Molecular approach to common causes of female infertility. Best Pract Res Clin Obstet Gynaecol 2002; 16: 685–702.

[18] Treadwell MJ, Hassell K, Levine R, et al. Adult sickle cell quality-of-life measurement information system (ASCQ-Me): conceptual model based on review of the literature and formative research. Clin J Pain 2014; 30: 902–914.

[19] Lanzkron S, Carroll CP, Haywood C. Mortality rates and age at death from sickle cell disease: U.S., 1979-2005. Public Health Rep Wash DC 1974 2013; 128: 110–116.

[20] Wang CJ, Kavanagh PL, Little AA, et al. Quality-of-care indicators for children with sickle cell disease. Pediatrics 2011; 128: 484–493.

[21] Cober MP, Phelps SJ. Penicillin Prophylaxis in Children with Sickle Cell Disease. J Pediatr Pharmacol Ther JPPT 2010; 15: 152–159.

[22] Hardie R, King L, Fraser R, et al. Prevalence of pneumococcal polysaccharide vaccine administration and incidence of invasive pneumococcal disease in children in Jamaica aged over 4 years with sickle cell disease diagnosed by newborn screening. Ann Trop Paediatr 2009; 29: 197–202.

[23] Ellison AM, Ota KV, McGowan KL, et al. Pneumococcal bacteremia in a vaccinated pediatric sickle cell disease population. Pediatr Infect Dis J 2012; 31: 534–536.

[24] Lee MT, Piomelli S, Granger S, et al. Stroke Prevention Trial in Sickle Cell Anemia (STOP): extended follow-up and final results. Blood 2006; 108: 847–852.

[25] Malouf AJ, Hamrick-Turner JE, Doherty MC, et al. Implementation of the STOP protocol for Stroke Prevention in Sickle Cell Anemia by using duplex power Doppler imaging. Radiology 2001; 219: 359–365.

[26] Charache S. Hydroxyurea as treatment for sickle cell anemia. Hematol Oncol Clin North Am 1991; 5: 571–583.

[27] Jacob SA, Mueller EL, Cochrane AR, et al. Variation in hospital admission of sickle cell patients from the emergency department using the Pediatric Health Information System. Pediatr Blood Cancer 2020; 67: e28067.

[28] Ep V, La S, Lh C, et al. Acute chest syndrome in sickle cell disease: clinical presentation and course. Cooperative Study of Sickle Cell Disease. Blood; 89, https://pubmed.ncbi.nlm.nih.gov/9057664/ (1997, accessed 16 November 2022).

[29] Powars D, Weidman JA, Odom-Maryon T, et al. Sickle cell chronic lung disease: prior morbidity and the risk of pulmonary failure. Medicine (Baltimore) 1988; 67: 66–76.

@article{1707175,
      author = {Dr. Idowu Olusola K., Dr Sanusi A. A., Dr. Owoade O. A.},
      title = {Intensive Care Management of Sickle Cell Disease},
      journal = {Iconic Research And Engineering Journals},
      year = {2025},
      volume = {8},
      number = {8},
      pages = {922-928},
      issn = {2456-8880},
      url = {https://www.irejournals.com/formatedpaper/1707175.pdf},
      abstract = {Sickle cell disease (SCD) is one of the most common hereditary disorders in the world, and it is most prevalent in the Middle East, the Mediterranean region, Southeast Asia, and sub-Saharan Africa, particularly in Nigeria. Sickle cell disease (SCD) is an autosomal recessive blood illness that is marked by clinical variability that may be influenced by environmental variables, racial and ethnic identity, socioeconomic status, and genetic and epigenetic factors. A variety of genotypes resulted in SCD characterized by the presence of one ?s gene and one of the following genes: another ?s (homozygous disease known as sickle cell anemia), a hemoglobin C gene, a gene for ?+ or ??-thalassemia or a hemoglobin D or hemoglobin E gene. Sickle cell anemia (SCA) is the most common genetic variant of SCD, accounting for 70% of cases worldwide.},
      month = {February},
  }